KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 129 filers reported holding KARYOPHARM THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.44 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $7,605,674 | -25.1% | 5,675,876 | 0.0% | 0.72% | -12.3% |
Q2 2023 | $10,159,818 | -54.0% | 5,675,876 | 0.0% | 0.82% | -55.1% |
Q1 2023 | $22,079,158 | +14.8% | 5,675,876 | +0.4% | 1.83% | +11.6% |
Q4 2022 | $19,229,298 | -37.4% | 5,655,676 | +0.6% | 1.64% | -32.5% |
Q3 2022 | $30,694,000 | +21.1% | 5,621,533 | 0.0% | 2.43% | +9.8% |
Q2 2022 | $25,353,000 | -38.8% | 5,621,533 | 0.0% | 2.21% | -31.0% |
Q1 2022 | $41,431,000 | +17.8% | 5,621,533 | +2.8% | 3.20% | +42.5% |
Q4 2021 | $35,175,000 | +12.3% | 5,470,452 | +1.6% | 2.25% | +18.9% |
Q3 2021 | $31,329,000 | -43.6% | 5,383,052 | 0.0% | 1.89% | -38.2% |
Q2 2021 | $55,553,000 | -1.5% | 5,383,052 | +0.4% | 3.06% | -4.8% |
Q1 2021 | $56,426,000 | -30.8% | 5,363,652 | +1.8% | 3.22% | -24.8% |
Q4 2020 | $81,543,000 | +9.8% | 5,267,652 | +3.6% | 4.28% | +4.9% |
Q3 2020 | $74,258,000 | -7.1% | 5,086,152 | +20.5% | 4.08% | -15.0% |
Q2 2020 | $79,916,000 | -3.3% | 4,219,452 | -1.9% | 4.80% | -30.6% |
Q1 2020 | $82,601,000 | -6.2% | 4,299,901 | -6.4% | 6.92% | +42.6% |
Q4 2019 | $88,086,000 | +89.1% | 4,595,001 | -5.1% | 4.85% | +56.3% |
Q3 2019 | $46,581,000 | +47.8% | 4,842,150 | -8.0% | 3.10% | +102.5% |
Q2 2019 | $31,521,000 | +2.6% | 5,262,263 | 0.0% | 1.53% | +19.5% |
Q1 2019 | $30,732,000 | -30.0% | 5,262,263 | +12.3% | 1.28% | -45.1% |
Q4 2018 | $43,902,000 | -44.7% | 4,685,352 | +0.5% | 2.34% | -27.2% |
Q3 2018 | $79,416,000 | +0.2% | 4,663,324 | 0.0% | 3.21% | +1.4% |
Q2 2018 | $79,230,000 | +60.4% | 4,663,324 | +26.7% | 3.17% | +49.9% |
Q1 2018 | $49,385,000 | +45.1% | 3,679,978 | +3.8% | 2.11% | +44.2% |
Q4 2017 | $34,027,000 | -11.4% | 3,544,439 | +1.3% | 1.46% | -9.5% |
Q3 2017 | $38,414,000 | +22.4% | 3,498,585 | +0.9% | 1.62% | +10.4% |
Q2 2017 | $31,382,000 | -28.3% | 3,467,575 | +1.8% | 1.46% | -29.1% |
Q1 2017 | $43,739,000 | +45.4% | 3,406,475 | +6.4% | 2.07% | +20.5% |
Q4 2016 | $30,084,000 | +0.2% | 3,200,396 | +3.7% | 1.72% | -1.6% |
Q3 2016 | $30,025,000 | +42.5% | 3,085,849 | -1.7% | 1.74% | +9.6% |
Q2 2016 | $21,066,000 | -23.8% | 3,139,433 | +1.3% | 1.59% | -25.8% |
Q1 2016 | $27,635,000 | -33.0% | 3,098,145 | -0.5% | 2.14% | -6.5% |
Q4 2015 | $41,243,000 | +26.9% | 3,112,645 | +0.9% | 2.30% | +46.9% |
Q3 2015 | $32,493,000 | -31.0% | 3,085,745 | +78.2% | 1.56% | -25.4% |
Q2 2015 | $47,115,000 | +61.8% | 1,731,530 | +82.1% | 2.10% | +45.6% |
Q1 2015 | $29,111,000 | – | 951,032 | – | 1.44% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Delphi Management Partners VIII, L.L.C. | 2,263,006 | $13,170,000 | 9.51% |
Palo Alto Investors LP | 5,383,052 | $31,329,000 | 1.89% |
Birchview Capital, LP | 246,000 | $1,432,000 | 0.97% |
Rubric Capital Management LP | 3,375,758 | $19,647,000 | 0.55% |
Lombard Odier Asset Management (Switzerland) SA | 1,517,804 | $8,834,000 | 0.55% |
RICE HALL JAMES & ASSOCIATES, LLC | 1,401,861 | $8,159,000 | 0.30% |
AlphaCentric Advisors LLC | 136,000 | $792,000 | 0.20% |
Bridgefront Capital, LLC | 20,946 | $122,000 | 0.13% |
Hennion & Walsh Asset Management, Inc. | 407,474 | $2,371,000 | 0.12% |
Virtus ETF Advisers LLC | 44,364 | $258,000 | 0.11% |